DE60144050D1 - (Chinazolin-4-yl)piperazin-4-ylÜthiocarboxamide als Hemmer der Phosphorylierung eines PDGF-Rezeptors - Google Patents
(Chinazolin-4-yl)piperazin-4-ylÜthiocarboxamide als Hemmer der Phosphorylierung eines PDGF-RezeptorsInfo
- Publication number
- DE60144050D1 DE60144050D1 DE60144050T DE60144050T DE60144050D1 DE 60144050 D1 DE60144050 D1 DE 60144050D1 DE 60144050 T DE60144050 T DE 60144050T DE 60144050 T DE60144050 T DE 60144050T DE 60144050 D1 DE60144050 D1 DE 60144050D1
- Authority
- DE
- Germany
- Prior art keywords
- phosphorylation
- kinases
- pdgf receptor
- thiocarboxamide
- quinazolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000026731 phosphorylation Effects 0.000 title abstract 4
- 238000006366 phosphorylation reaction Methods 0.000 title abstract 4
- -1 (Quinazolin-4-yl) piperazin-4-yl-thiocarboxamide Chemical compound 0.000 title abstract 3
- 108091008606 PDGF receptors Proteins 0.000 title abstract 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 102000020233 phosphotransferase Human genes 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010061989 glomerulosclerosis Diseases 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22612100P | 2000-08-18 | 2000-08-18 | |
| PCT/US2001/041750 WO2002016361A2 (en) | 2000-08-18 | 2001-08-17 | Nitrogenous heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60144050D1 true DE60144050D1 (de) | 2011-03-31 |
Family
ID=22847635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60144050T Expired - Lifetime DE60144050D1 (de) | 2000-08-18 | 2001-08-17 | (Chinazolin-4-yl)piperazin-4-ylÜthiocarboxamide als Hemmer der Phosphorylierung eines PDGF-Rezeptors |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7329655B2 (de) |
| EP (1) | EP1309568B1 (de) |
| AT (1) | ATE498614T1 (de) |
| AU (1) | AU2001293208A1 (de) |
| DE (1) | DE60144050D1 (de) |
| ES (1) | ES2361582T3 (de) |
| WO (1) | WO2002016361A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE483693T1 (de) | 2000-08-18 | 2010-10-15 | Millennium Pharm Inc | N-aryl-ä4-ä7-(alkoxy)chinazolin-4- ylüpiperazinylücarboxamid-verbindungen als pdgf- rezeptoren hemmer |
| PT1315715E (pt) | 2000-08-18 | 2008-10-30 | Millennium Pharm Inc | Derivados de quianazolina utilizados como inibidores de quinase |
| AU2002217999A1 (en) | 2000-11-01 | 2002-05-15 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
| AU2002254152A1 (en) | 2001-03-08 | 2002-09-24 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
| WO2004041256A2 (en) * | 2002-11-08 | 2004-05-21 | Novo Nordisk A/S | Safe chemical uncouplers for the treatment of obesity |
| US20100179162A1 (en) * | 2005-07-20 | 2010-07-15 | Millennium Pharmaceuticals , Inc. | Crystal forms of 4-[6-methoxy-7(3-piperidin-1-yl-propoxy) quinazoline-4yl) piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide |
| CA2643044A1 (en) * | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| EP2370417A2 (de) * | 2008-11-21 | 2011-10-05 | Millennium Pharmaceuticals, Inc. | Lactatsalz von 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)chinazolin-4-yl]piperazin-1-carbonsäure-(4-isopropoxyphenyl)amid und pharmazeutische zusammensetzungen davon zur behandlung von krebs und anderen krankheiten bzw. störungen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0882717B1 (de) * | 1996-10-01 | 2010-09-08 | Kyowa Hakko Kirin Co., Ltd. | Stickstoff enthaltende heterocyclische verbindungen |
| AU3053999A (en) | 1998-03-31 | 1999-10-25 | Kyowa Hakko Kogyo Co. Ltd. | Nitrogenous heterocyclic compounds |
| AU2001293207A1 (en) | 2000-08-18 | 2002-03-04 | Cor Therapeutics, Inc. | Nitrogenous heterocyclic compounds |
| ATE483693T1 (de) | 2000-08-18 | 2010-10-15 | Millennium Pharm Inc | N-aryl-ä4-ä7-(alkoxy)chinazolin-4- ylüpiperazinylücarboxamid-verbindungen als pdgf- rezeptoren hemmer |
| PT1315715E (pt) | 2000-08-18 | 2008-10-30 | Millennium Pharm Inc | Derivados de quianazolina utilizados como inibidores de quinase |
| AU2002254152A1 (en) * | 2001-03-08 | 2002-09-24 | Millennium Pharmaceuticals | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
-
2001
- 2001-08-17 EP EP01973653A patent/EP1309568B1/de not_active Expired - Lifetime
- 2001-08-17 DE DE60144050T patent/DE60144050D1/de not_active Expired - Lifetime
- 2001-08-17 US US10/344,625 patent/US7329655B2/en not_active Expired - Fee Related
- 2001-08-17 ES ES01973653T patent/ES2361582T3/es not_active Expired - Lifetime
- 2001-08-17 WO PCT/US2001/041750 patent/WO2002016361A2/en active Application Filing
- 2001-08-17 AT AT01973653T patent/ATE498614T1/de not_active IP Right Cessation
- 2001-08-17 AU AU2001293208A patent/AU2001293208A1/en not_active Abandoned
-
2007
- 2007-12-18 US US11/959,341 patent/US8022071B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002016361A2 (en) | 2002-02-28 |
| AU2001293208A1 (en) | 2002-03-04 |
| EP1309568A2 (de) | 2003-05-14 |
| US8022071B2 (en) | 2011-09-20 |
| US20040176594A1 (en) | 2004-09-09 |
| EP1309568B1 (de) | 2011-02-16 |
| ATE498614T1 (de) | 2011-03-15 |
| WO2002016361A3 (en) | 2002-06-13 |
| US7329655B2 (en) | 2008-02-12 |
| ES2361582T3 (es) | 2011-06-20 |
| US20090176780A1 (en) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE402169T1 (de) | Quinazolin-derivate als kinase inhibitoren | |
| WO2002072578A3 (en) | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases | |
| NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
| DE60143204D1 (de) | N-aryl-ä4-Ä7-(alkoxy)Chinazolin-4-ylÜPiperazinylüCarboxamid-Verbindungen als PDGF-Rezeptoren Hemmer | |
| BRPI0417697A (pt) | inibidores de protease de aspartila heterocìclicos | |
| BRPI0513565A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
| BRPI0418231A (pt) | compostos de pirrolotriazina como inibidores da cinase | |
| CA2400447A1 (en) | Kinase inhibitors | |
| MY134848A (en) | Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases | |
| WO2004001059A3 (en) | Heterocyclic inhibitors of kinases | |
| BR9913903A (pt) | Composto, método para tratar ou impedir um estado doentio, e, composição farmacêutica | |
| ATE240328T1 (de) | Substituierte azaoxindolederivate | |
| ATE239012T1 (de) | Triazin angiogenese-inhibitoren | |
| DE60144050D1 (de) | (Chinazolin-4-yl)piperazin-4-ylÜthiocarboxamide als Hemmer der Phosphorylierung eines PDGF-Rezeptors | |
| Brooks et al. | Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data | |
| WO2002016360A3 (en) | Nitrogenous heterocyclic compounds | |
| ATE502928T1 (de) | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung | |
| ATE360423T1 (de) | Verwendung von chymase hemmern gegen vaskuläre lipidablagerung | |
| ATE421510T1 (de) | Kompetitive atp-kinasehemmer | |
| WO2024044744A3 (en) | Peroxiredoxin 3 inhibitors and methods of use for treating cancer | |
| RU99116012A (ru) | Гетероциклические производные карбоновой кислоты, их получение и их применение в качестве антагонистов рецепторов эндотелина | |
| TH48285A (th) | อะโทรปไอโซเมอร์ 3-เฮเทอโรอาริล 4(3h) ควินาโซลิโนน | |
| RU2001107024A (ru) | Новые производные карбоновой кислоты, имеющие боковые кетоцепи, их получение и применение в качестве антагонистов рецепторов эндотелина |